Actavis inaugurates new manufacturing plant
Actavis Group has inaugurated a new expansion pharmaceutical manufacturing plant in Iceland.
Actavis said the new site will not use fossil fuel in tablet manufacturing and packaging, generating zero carbon footprint.
The company has invested about EUR8m in the expansion.
Following the expansion, the production capacity of the Hafnarfjordur, Iceland site will be about 1.5 billion tablets, around 96% of which are exported to the European markets.
Actavis CEO Claudio Albrecht said the site is 100% powered by geothermal energy, and is therefore the most eco-friendly pharmaceutical facility in the world.
"It meets both the ISO14001 environmental standard and the OHSAS18001 health- and safety standard, reflecting the strong Environment, health and safety commitment of our company," Albrecht said.
"This latest investment increases the production capacity in Iceland by 50%, giving us a significantly increased launch capability for the EU market."
Related Insight
Suppliers Directory
Tecnosoft - Monitoring Systems for Temperature, Humidity and Pressure
Tecnosoft is a system development company working for big third party companies while also steering its own product line with its own brand. We have a lot of experience and a great know-how in the medical and geotechnical industry, having developed and produced data acquisition systems for both markets, in Italy and all around the world, for different leading companies.
Production & Manufacturing > Process & Production > Suppliers
IKA® - Global Leaders in Mixing Technology
The IKA® Group is a global market leader for laboratory equipment, analytical and process technology. Magnetic stirrers, overhead stirrers, dispersers, shakers, mills, rotary evaporator, calorimeters, laboratory reactors and incubation shakers make up the laboratory and analytical equipment portfolio.
Production & Manufacturing > Process & Production > Suppliers
Geodis Wilson - Global Pharmaceutical Freight Management Services
Geodis Wilson is a leading global freight management company. They manage sea and air cargo across five continents, making supply chains transparent and flexible to handle.
Production & Manufacturing > Process & Production > Suppliers
DASGIP - Parallel Bioreactor Systems for Unparalleled Results
Rapid technological advances in biotech and pharmaceutical industries have created increasing demands in research and development. DASGIP Parallel Bioreactor Systems for the cultivation of bacterial, phototrophic, animal and human cells at bench top scale support scientists and engineers to accomplish their projects quicker and more efficiently.
Production & Manufacturing > Process & Production > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Process & Production Intelligence
GRACO's New FDA Pumps
Published by GRACO PBR
Production & Manufacturing > Process & Production > White Papers
Continuous Process Powder Wetting
Published by IKA®
Production & Manufacturing > Process & Production > White Papers
MiniColumns for 96 Array Chromatography
Published by Atoll
Production & Manufacturing > Process & Production > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.